144 related articles for article (PubMed ID: 18601734)
1. Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer.
Sobral RA; Honda ST; Katayama ML; Brentani H; Brentani MM; Patrão DF; Folgueira MA
Acta Vet Scand; 2008 Jul; 50(1):27. PubMed ID: 18601734
[TBL] [Abstract][Full Text] [Related]
2. Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Barros Filho MC; Katayama ML; Brentani H; Abreu AP; Barbosa EM; Oliveira CT; Góes JC; Brentani MM; Folgueira MA
Braz J Med Biol Res; 2010 Dec; 43(12):1225-31. PubMed ID: 21103787
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.
Folgueira MA; Carraro DM; Brentani H; Patrão DF; Barbosa EM; Netto MM; Caldeira JR; Katayama ML; Soares FA; Oliveira CT; Reis LF; Kaiano JH; Camargo LP; Vêncio RZ; Snitcovsky IM; Makdissi FB; e Silva PJ; Góes JC; Brentani MM
Clin Cancer Res; 2005 Oct; 11(20):7434-43. PubMed ID: 16243817
[TBL] [Abstract][Full Text] [Related]
4. Expression of glutathione, glutathione peroxidase and glutathione S-transferase pi in canine mammary tumors.
Leonel C; Gelaleti GB; Jardim BV; Moschetta MG; Regiani VR; Oliveira JG; Zuccari DA
BMC Vet Res; 2014 Feb; 10():49. PubMed ID: 24565113
[TBL] [Abstract][Full Text] [Related]
5. Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.
Zambrano-Estrada X; Landaverde-Quiroz B; Dueñas-Bocanegra AA; De Paz-Campos MA; Hernández-Alberto G; Solorio-Perusquia B; Trejo-Mandujano M; Pérez-Guerrero L; Delgado-González E; Anguiano B; Aceves C
BMC Vet Res; 2018 Mar; 14(1):87. PubMed ID: 29530037
[TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs.
Simon D; Knebel JW; Baumgartner W; Aufderheide M; Meyer-Lindenberg A; Nolte I
Am J Vet Res; 2001 Nov; 62(11):1825-30. PubMed ID: 11703031
[TBL] [Abstract][Full Text] [Related]
7. Aldoxorubicin-loaded nanofibers are cytotoxic for canine mammary carcinoma and osteosarcoma cell lines in vitro: A short communication.
Stokol T; Wan C; Blakely R; Bellat V; Law B
Res Vet Sci; 2020 Feb; 128():86-89. PubMed ID: 31760317
[TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel.
Simon D; Schoenrock D; Baumgärtner W; Nolte I
J Vet Intern Med; 2006; 20(5):1184-90. PubMed ID: 17063714
[TBL] [Abstract][Full Text] [Related]
9. Effects of doxorubicin associated with amniotic membrane stem cells in the treatment of canine inflammatory breast carcinoma (IPC-366) cells.
Borghesi J; Caceres S; Mario LC; Alonso-Diez A; Silveira Rabelo AC; Illera MJ; Silvan G; Miglino MA; Favaron PO; Carreira ACO; Illera JC
BMC Vet Res; 2020 Sep; 16(1):353. PubMed ID: 32972410
[TBL] [Abstract][Full Text] [Related]
10. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour.
Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T
Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327
[TBL] [Abstract][Full Text] [Related]
11. Characterization of protein marker expression, tumorigenicity, and doxorubicin chemoresistance in two new canine mammary tumor cell lines.
Hsiao YL; Hsieh TZ; Liou CJ; Cheng YH; Lin CT; Chang CY; Lai YS
BMC Vet Res; 2014 Sep; 10():229. PubMed ID: 25267010
[TBL] [Abstract][Full Text] [Related]
12. The effect of small interfering RNA (siRNA) against the Bcl-2 gene on apoptosis and chemosensitivity in a canine mammary gland tumor cell line.
Nagamatsu K; Tsuchiya F; Oguma K; Maruyama H; Kano R; Hasegawa A
Res Vet Sci; 2008 Feb; 84(1):49-55. PubMed ID: 17537469
[TBL] [Abstract][Full Text] [Related]
13. A novel approach to treatment of lymphangiosarcoma in a boxer dog.
Marcinowska A; Warland J; Brearley M; Dobson J
J Small Anim Pract; 2013 Jun; 54(6):334-7. PubMed ID: 23560802
[TBL] [Abstract][Full Text] [Related]
14. Reduced canine BRCA2 expression levels in mammary gland tumors.
Yoshikawa Y; Morimatsu M; Ochiai K; Ishiguro-Oonuma T; Wada S; Orino K; Watanabe K
BMC Vet Res; 2015 Jul; 11():159. PubMed ID: 26202431
[TBL] [Abstract][Full Text] [Related]
15. Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.
Thumser-Henner P; Nytko KJ; Rohrer Bley C
BMC Vet Res; 2020 Jan; 16(1):30. PubMed ID: 32005245
[TBL] [Abstract][Full Text] [Related]
16. Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.
Bakirel T; Alkan FÜ; Üstüner O; Çinar S; Yildirim F; Erten G; Bakirel U
J Vet Med Sci; 2016 May; 78(4):657-68. PubMed ID: 26822118
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of melatonin treatment in primary culture of canine mammary tumors.
Lopes JR; Maschio LB; Jardim-Perassi BV; Moschetta MG; Ferreira LC; Martins GR; Gelaleti GB; De Campos Zuccari DA
Oncol Rep; 2015 Jan; 33(1):311-9. PubMed ID: 25384569
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of the BRCA1 splicing variants in canine normal tissues and mammary gland tumors.
Sugiura T; Matsuyama S; Akiyosi H; Takenaka S; Yamate J; Kuwamura M; Aoki M; Shimada T; Ohashi F; Kubo K
J Vet Med Sci; 2007 Jun; 69(6):587-92. PubMed ID: 17611353
[TBL] [Abstract][Full Text] [Related]
19. Global gene expression profile in canine mammary carcinomas.
Varallo GR; Jardim-Perassi BV; Alexandre PA; Fukumasu H; Zuccari DAPC
Vet J; 2019 Dec; 254():105393. PubMed ID: 31836163
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of doxorubicin-based chemotherapy for non-resectable canine subcutaneous haemangiosarcoma.
Wiley JL; Rook KA; Clifford CA; Gregor TP; Sorenmo KU
Vet Comp Oncol; 2010 Sep; 8(3):221-33. PubMed ID: 20691029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
